β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China

Table 2 Susceptibility of the Moraxella catarrhalis isolates in Youyang, Zhongjiang and total profiles according to EUCAST, CLSI and BSAC

	Antibiotics^*	Youyang					Zhongjiang					Total
	Antibiotics^*	I%	R%	MIC50	MIC90	MIC Range	I%	R%	MIC50	MIC90	MIC Range	I%	R%	MIC50	MIC90	MIC Range
EUCAST^a	AMP	–	–	2	4	0.016~ 16	–	–	2	6	0.032~ 12	–	–	2	6	0.032–12
	AMC	–	0	0.19	0.38	0.016~ 0.38	–	0	0.25	0.25	0.016~ 0.38	–	0	0.25	0.25	0.016–0.38
	CXM	8.9	0	2	4	0.023~ 8	18.2	1.3	3	6	0.047~ 16	12.9	0.6	3	6	0.047–16
	CAZ	–	–	0.125	0.38	0.023~ 2	–	–	0.094	0.38	0.032~ 1	–	–	0.094	0.38	0.032–1
	FEP	–	4.0	1.5	4	0.064~ 6	–	1.3	1.5	4	0.19~ 6	–	2.8	1.5	4	0.19–6
	CIP	–	2.0	0.047	0.19	0.016~ 1	–	5.2	0.047	0.094	0.016~ 1	–	3.4	0.047	0.094	0.016–1
	ERY	28.7	64.4	0.75	> 256	0.047~ > 256	11.7	79.2	2	> 256	0.19~ > 256	21.3	70.8	2	256	0.19- > 256
	MEM	–	0	0.006	0.008	0.003~ 0.38	–	0	0.006	0.008	0.003~ 0.023	–	0	0.006	0.008	0.003–0.38
	TCY	3.0	5.9				0	3.9				1.7	5.1
	CHL	–	4.0				–	3.9				–	3.9
	SXT	9.9	30.7				7.8	3.9				9.0	19.1
CLSI^b	AMC	–	0	0.19	0.38	0.016~ 0.38	–	0	0.25	0.25	0.016~ 0.38	–	0	0.25	0.25	0.016–0.38
	CXM	8.9	0	2	4	0.023~ 8	18.2	1.3	3	6	0.047~ 16	12.9	0.6	3	6	0.047–16
	CAZ	-^#	-^#	0.125	0.38	0.023~ 2	-^#	-^#	0.094	0.38	0.032~ 1	-^#	-^#	0.094	0.38	0.032–1
	CIP	-^#	-^#	0.047	0.19	0.016~ 1	-^#	-^#	0.047	0.094	0.016~ 1	-^#	-^#	0.047	0.094	0.016–1
	ERY	48.5	15.8	0.75	> 256	0.047~ > 256	44.1	35.1	2	> 256	0.19~ > 256	47.8	23.0	2	> 256	0.19- > 256
	TCY	20.8	5.9				3.9	3.9				13.5	5.1
	SXT	6.9	16.8				0	1.3				3.9	10.1
BSAC^c	AMP	–	68.3	2	4	0.016~ 16	–	81.8	2	6	0.032~ 12	–	74.2	2	6	0.032–12
	CXM	45.5	49.5	2	4	0.023~ 8	44.2	53.2	3	6	0.047~ 16	44.9	51.1	3	6	0.047–16
	TCY	–	5.9				–	3.9				–	5.1
	SXT	–	19.8				–	1.3				–	11.8

^aEUCAST European Committee on Antimicrobial Susceptibility Testing, ^bCLSI Clinical and Laboratory Standards Institute, ^cBSAC British Society for Antimicrobial Chemotherapy, ^*AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, ^# no breakpoints were listed in the according criterion, but the other “-“s mean no data

ISSN: 1471-2180